Mao Inhibitors + Avutometinib Potassium And Defactinib Hydrochloride Interaction
Majorinteraction on record
Description
Concomitant use increases defactinib exposure, which may increase the risk of adverse reactions. Avoid concomitant use.
Mechanism
Defactinib is a CYP3A4 substrate; inhibition increases exposure
Source: NLP:avutometinib potassium and defactinib hydrochloride